-
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
08 Jan 2025 13:10 GMT
… extensive-stage small cell lung cancer (ES-SCLC).
“This … Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin … phase III trial of amrubicin versus topotecan as second … cell lung cancer progression after 2 lines of therapy. Lung Cancer. …
-
New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer
09 Aug 2024 18:41 GMT
… living with small cell lung cancer face poor outcomes with … I-DXd compared to amrubicin, lurbinectedin or topotecan … With Relapsed Small Cell Lung Cancer (IDeate-Lung02)
ClinicalTrials. … ;NCT06203210
3. Small Cell Lung Cancer Treatment (PDQ)–Patient Version …
-
MSD, Daiichi Sankyo lung cancer ADC starts phase 3
05 Aug 2024 11:17 GMT
… -DXd against second-line options amrubicin, lurbinectedin, or topotecan. The dual … type of lung cancer, accounting for about 15% of all lung cancers, with overexpression … EGFR-mutated non-small-cell lung cancer (NSCLC). The regulator gave manufacturing …
-
First subject dosed in IDeate─Lung02 phase 3 trial of ifinatamab deruxtecan in patients with relapsed small cell lung cancer
03 Aug 2024 05:04 GMT
… with relapsed small cell lung cancer (SCLC) versus treatment … 2023 World Conference on Lung Cancer hosted by the … s choice of chemotherapy (amrubicin, lurbinectedin or topotecan) in … lung cancer cases were diagnosed globally in 2022. Small cell lung cancer …
-
Daiichi Sankyo and MSD announce first subject dosing in lung cancer trial
02 Aug 2024 11:51 GMT
… people with relapsed small cell lung cancer (SCLC).
Discovered by … choice of chemotherapy comprising amrubicin, lurbinectedin or topotecan.
… living with small cell lung cancer face poor outcomes with … types of small cell lung cancer.”
Daiichi Sankyo and MSD …
-
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
01 Aug 2024 13:53 GMT
… with relapsed small cell lung cancer (SCLC) versus treatment … 2023 World Conference on Lung Cancer hosted by the International … s choice of chemotherapy (amrubicin, lurbinectedin or topotecan) in … Cell Lung Cancer
More than 2.48 million lung cancer cases …
-
Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC
28 Oct 2024 15:49 GMT
… regimens like amrubicin, topotecan, and lurbinectedin for relapsed small cell lung cancer, while …
-
FDA APPROVES IMDELLTRA , THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
17 May 2024 05:23 GMT
… References
American Cancer Society. Lung Cancer Survival Rates. www.cancer … patients with small cell lung cancer. Lung Cancer. 2020;147:237- … III trial of amrubicin versus topotecan as second … cell lung cancer progression after 2 lines of therapy. Lung Cancer . …
-
Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches
21 Dec 2023 04:45 GMT
… lung cancers. The two broad histological subtypes of lung cancer are small cell lung cancer … specifically accumulate in lung tumor tissues, improving drug … targeted delivery to lung tumors is a promising … lung cancer. Von Pawel et al reported that amrubicin, …
-
Could Your Patients Benefit? New Trials in Lung Cancer
20 Sep 2023 13:59 GMT
… advanced non–small cell lung cancer (NSCLC). Adult patients … with this type of lung cancer are eligible for another … clinicaltrials.gov.
Small cell lung cancer (SCLC) relapsed after … Zepzelca), topotecan (Hycamtin), or amrubicin (Calsed) in some countries. …
About
© 1995-2025